Axial Biotherapeutics – pharmaceutical daily

July 16, 2019 Off

Axial Biotherapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AB-2004 for Treatment of Gastrointestinal Dysfunction and Associated Behavioral Symptoms of Autism Spectrum Disorder

WALTHAM, Mass.–(BUSINESS WIRE)–Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and…

June 20, 2019 Off

Axial Biotherapeutics bags $10M Investment from Taiho Ventures to Access Axial’s Expertise in the Gut-Brain Axis

By BusinessWire

$10M investment as Series B extension, bringing total amount raised to $35M –

– Direct investment for the discovery of gut targeted, small molecule therapeutics in oncology utilizing Axial’s novel platform technology

May 2, 2019 Off

Axial Biotherapeutics develops AB-2004 as potential treatment for gastrointestinal dysfunction

By BusinessWire

– Preclinical results support development of AB-2004 as potential treatment for gastrointestinal dysfunction and associated behavioral symptoms of Autism Spectrum…